The in vitro and in vivo antibacterial activities of the new rifamycin derivatives KRM-1648 and KRM-1657 were compared with those of rifampin. Rifabutin, ciprofloxacin, and clarithromycin were also tested for reference. The respective MICs of KRM-1648 and KRM-1657 for 90% of the strains tested (MIC90s) were 0.016 and 0.0078 ,ug/ml, respectively, for methicillin-susceptible Staphylococcus aureus, 0.016 and 0.0039 ,ug/ml, respectively, for methicillin-resistant S. aureus, and 0.0625 and 0.016 ,ug/ml, respectively, for methicillin-and quinolone-resistant S. aureus. These MIC90s of KRM-1657 were equal to or 2-to 64-fold lower than those of rifampin. KRM-1648 and KRM-1657 with MIC90s of between 0.002 and 0.078 ,ug/ml were 2-to 128-fold more active than rifampin against Staphylococcus epidermidis and Streptococcus species, including Streptococcus pneumoniae and Streptococcus pyogenes. The MIC90s of KRM-1657 for Haemophilus influenzae and Neisseria gonorrhoeae were 0.25 and 0.1 ,ug/ml, respectively; KRM-1657 was almost as active as rifampin and was 8-to 16-fold more active than KRM-1648 against these strains. The frequency of occurrence of spontaneous mutations to resistance to KRM-1648 and KRM-1657 was equal to that to rifampin. Against systemic infection with S. aureus in mice, the efficacies of KRM-1648 and KRM-1657 were comparable to that of rifampin.
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The recently synthesized rifamycin derivatives 3'-hydroxy-5'-(4-isobutyl-1 -piperazinyl)benzoxazinorifamycin (KRM-1648) and 3'-hydroxy-5'-(4-propyl-1-piperazinyl)benzoxazinorifamycin (KRM-1657) ( Fig. 1 ) exhibit potent activity against a variety of mycobacteria including Mycobacterium tuberculosis, Mycobacterium avium, and Mycobacterium intracellulare (1, 3, 6, 7, 9, 10) . These compounds have also been shown to be active against Staphylococcus aureus and Bacillus subtilis but have been shown to be inactive against Escherichia coli and Klebsiella pneumoniae (10) . In the study described here, we conducted further testing to determine the in vitro activities of KRM compounds against gram-positive and gram-negative bacteria with the aim of elucidating their antibacterial properties. The frequency of occurrence of spontaneous mutants of S. aureus resistant to these compounds and the therapeutic efficacies of these compounds against S. aureus infections in mice were also determined. MATERIALS then administered orally to infected mice in a volume of 0.1 ml/10 g of body weight.
Determination of MICs. The MICs were determined by the broth microdilution method. The media used for MIC determination were cation-supplemented Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.) and Mueller-Hinton broth supplemented with 5% lysed horse blood-15 ,ug of NAD per ml-5 mg of yeast extract (Difco) per ml to support the growth of Streptococcus pneumoniae, Streptococcus pyogenes, and Haemophilus influenzae. Gifu Anaerobic Medium broth (Nissui Pharmaceutical, Tokyo, Japan) was used for obligate anaerobes. The MICs for Neisseria gonorrhoeae were determined by the twofold serial agar dilution method. The media contained GC agar (Difco) supplemented with 2% defined supplemented solution (20 g of glucose, 0.5 g of glutamine, and 0.001 g of cocarboxylase in 100 ml of distilled water).
An overnight broth culture (about 108 CFU/ml) of a bacterial suspension, prepared by transferring bacterial colonies grown on suitable agar plates into saline, was diluted with saline, and the mixture was inoculated into drug-containing wells to a final concentration of ca. 5 x 105 CFU/ml (aerobic bacteria) or 5 x 106 CFU/ml (anaerobic bacteria). After incubation of microtiter plates at 35°C for 18 to 24 h, the MIC, calculated by the method of van der Waerden (8). All untreated mice died within 1 day after inoculation.
RESULTS
Antibacterial activity. The results of susceptibility testing of standard strains of bacteria are given in Tables 1 and 2. KRM-1648 and KRM-1657 exhibited strong activity against gram-positive bacteria but were inactive against most of the gram-negative bacteria tested. The spectra of antibacterial activities of the KRM compounds were similar to those of rifampin and rifabutin.
The activities of KRM compounds against 180 clinical isolates of bacteria are given in Table 3 . KRM-1657 and KRM-1648 exhibited potent activity against both methicillinsusceptible S. aureus (MICs for 90% of strains tested [MIC90s], 0.0078 and 0.016 jig/ml, respectively) and methicillin-resistant S. aureus (MIC90s, 0.0039 and 0.016 ,ug/ml, respectively). They had activities comparable to that of rifampin (MIC90s, 0.0078 and 0.0078 p.g/ml, respectively) and were more active than the other drugs tested. Against methicillin-and quinolone-resistant S. aureus, KRM-1657 was the most active compound (MIC90, 0.016 ,ug/ml) among the drugs tested. Against Staphylococcus epidermidis, S. pneumoniae, and S. pyogenes, KRM-1657 and KRM-1648 exhibited potent activity, with MIC90s ranging from 0.002 to 0.0078 p.g/ml; their activities against these strains were much greater than those of the reference drugs tested. Against H. influenzae, KRM-1657 exhibited good activity (MIC90, 0.25 ,ug/ml), comparable to those of rifampin and rifabutin, and was more active than KRM-1648 and clarithromycin but was less active than ciprofloxacin. Against non -penicillinase -producing-and penicillinase -producing strains of N. gonorrhoeae, KRM-1657 also exhibited good activity (MIC9,,, 0.1 ,ug/ml), as did rifampin; its activity against these strains was greater than those of the other drugs tested.
Frequency of occurrence of spontaneous mutants. The frequency of occurrence of spontaneous mutants of S. aureus 209-P resistant to the test drugs is given in Table 4 . The concentration used for selection was four times the corresponding MIC, and colonies that grew on agar plates were considered resistant to the respective drugs; MICs were in some cases more than 16-fold higher (for KRM compounds, rifampin, and rifabutin) and in other cases were 8-fold higher (for ciprofloxacin) than those before selection (data not shown). The frequency of occurrence of spontaneous mutants of S. aureus 209-P resistant to the KRM compounds (1.1 x 10-6 for KRM-1648; 1.6 x 10-6 for KRM-1657) was almost the same as those to rifampin (3.2 x 10-6) and rifabutin (1.2 x 10-6), but greater than those to ciprofloxacin (1.0 x 10-7) and clarithromycin (<5.0 x 10-8).
In vivo efficacy in mice. The in vivo efficacies of the KRM compounds were compared with those of rifampin and rifabutin against septicemia caused by S. aureus infection in mice. The results are summarized in Table 5 (1, 3, 6, 7, 9, 10) .
The findings of the present study demonstrated that KRM-1648 and KRM-1657 have antibacterial activity against grampositive bacteria, but they have poor activity against most of the gram-negative bacteria tested. The spectra of antibacterial activities of both of these KRM compounds were almost the same as those of rifampin and rifabutin.
Of the four rifamycin derivatives tested, KRM-1657 was the most active against most bacteria; this was followed by rifampin, KRM-1648, and rifabutin. Although the activity of KRM-1657 against methicillin-susceptible and -resistant S. aureus was only comparable to or slightly greater than those of rifampin and KRM-1648 against methicillin-and quinoloneresistant S. aureus, it was 4-and 64-fold more active than KRM-1648 and rifampin, respectively. KRM-1648 and KRM- 
